+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Epilepsy (Central Nervous System) - Drugs In Development, 2021

  • ID: 5359557
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 789 pages
  • Global Markets Direct

FEATURED COMPANIES

  • a:head Bio AG
  • Accure Therapeutics SL
  • AfaSci Inc
  • Anavex Life Sciences Corp
  • Apteeus
  • Auris Medical Holding Ltd
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Epilepsy (Central Nervous System) - Drugs In Development, 2021, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape.

Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and short periods of unconsciousness or convulsions. Symptoms of epilepsy are repeated seizures, weakness, and anxiety, loss of consciousness and contraction, or jerking, of body muscles. Main causes of epilepsy include low oxygen during birth, head injuries that occur during birth or from accidents during youth or adulthood, brain tumors, genetic conditions that result in brain injury, such as tuberous sclerosis, infections such as meningitis or encephalitis, and stroke or any other type of damage to the brain.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Epilepsy (Central Nervous System) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Epilepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epilepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 12, 32, 29, 4, 124, 38 and 5 respectively. Similarly, the Universities portfolio in Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 25 and 3 molecules, respectively.

Epilepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Epilepsy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Epilepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Epilepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Epilepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Epilepsy (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Epilepsy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Epilepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • a:head Bio AG
  • Accure Therapeutics SL
  • AfaSci Inc
  • Anavex Life Sciences Corp
  • Apteeus
  • Auris Medical Holding Ltd
  • MORE
  • Introduction
  • Epilepsy - Overview
  • Epilepsy - Therapeutics Development
  • Epilepsy - Therapeutics Assessment
  • Epilepsy - Companies Involved in Therapeutics Development
  • Epilepsy - Drug Profiles
Epilepsy - Dormant Projects

Epilepsy - Discontinued Products
  • Epilepsy - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Epilepsy, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Epilepsy - Pipeline by a:head Bio AG, 2021
  • Epilepsy - Pipeline by Aadi Bioscience Inc, 2021
  • Epilepsy - Pipeline by Accure Therapeutics SL, 2021
  • Epilepsy - Pipeline by Advanced Neural Dynamics Inc, 2021
  • Epilepsy - Pipeline by Advicenne SA, 2021
  • Epilepsy - Pipeline by Aequus Pharmaceuticals Inc, 2021
  • Epilepsy - Pipeline by AfaSci Inc, 2021
  • Epilepsy - Pipeline by Affectis Pharmaceuticals AG, 2021
  • Epilepsy - Pipeline by AgoneX Biopharmaceuticals Inc, 2021
  • Epilepsy - Pipeline by AMO Pharma Ltd, 2021
  • Epilepsy - Pipeline by Anavex Life Sciences Corp, 2021
  • Epilepsy - Pipeline by Aphios Corp, 2021
  • Epilepsy - Pipeline by Apteeus, 2021
  • Epilepsy - Pipeline by Aquestive Therapeutics Inc, 2021
  • Epilepsy - Pipeline by Aucta Pharmaceuticals LLC, 2021
  • Epilepsy - Pipeline by Auris Medical Holding Ltd, 2021
List of Figures
  • Number of Products under Development for Epilepsy, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021
Note: Product cover images may vary from those shown
  • a:head Bio AG
  • Aadi Bioscience Inc
  • Accure Therapeutics SL
  • Advanced Neural Dynamics Inc
  • Advicenne SA
  • Aequus Pharmaceuticals Inc
  • AfaSci Inc
  • Affectis Pharmaceuticals AG
  • AgoneX Biopharmaceuticals Inc
  • AMO Pharma Ltd
  • Anavex Life Sciences Corp
  • Aphios Corp
  • Apteeus
  • Aquestive Therapeutics Inc
  • Aucta Pharmaceuticals LLC
  • Auris Medical Holding Ltd
  • Aurum Biosciences Ltd
  • Avicanna Inc
  • Axium Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll